Real-World Data Presented at TCT 2025 Demonstrates the EggNest Complete Radiation Protection System Significantly Reduces Radiation Exposure for the Entire Cath Lab Team
SAN FRANCISCO, Oct. 26, 2025 /PRNewswire/ -- At the 2025 Transcatheter Cardiovascular…
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…
Paris 2024 Fair Play Awards presented at Olympic Museum
13 October 2025 - Decathlete Sander Skotheim, the German Olympic Sports Confederation (DOSB)…
Tommy Fleetwood of Team Europe wins Nicklaus-Jacklin Award presented by Aon at 45th Ryder Cup
Award given to one outstanding player who embodies the true spirit of…
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association (ATA) Annual Meeting
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results…
New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl…
Guidelines for Osstem Implants, Implant Fracture and Peripheral Diseases are Presented
Listed in the prestigious international academic journal, MDPI 'Prosthesis' SEOUL, South Korea,…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase…
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal…
